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We examined the immune microenvironment of pri-
mary colorectal cancer (CRC) using immunohistochem-
istry, laser capture microdissection/qRT-PCR, flow
cytometry and functional analysis of tumor infiltrating
lymphocytes. A subset of CRC displayed high infiltration
with activated CD8+ CTL as well as activated Th1 cells
characterized by IFN-gamma production and the Th1
transcription factor Tbet. Parallel analysis of tumor gen-
otypes revealed that virtually all of the tumors with this
active Th1/CTL microenvironment had defects in mis-
match repair, as evidenced by microsatellite instability
(MSI). Counterbalancing this active Th1/CTL microen-
vironment, MSI tumors selectively demonstrated highly
up-regulated expression of multiple immune check-
points, including five - PD-1, PD-L1, CTLA-4, LAG-3
and IDO - currently being targeted clinically with inhi-
bitors. These findings link tumor genotype with the
immune microenvironment, and explain why MSI
tumors are not naturally eliminated despite a hostile
Th1/CTL microenvironment. They further suggest that
blockade of specific checkpoints may be selectively effi-
cacious in the MSI subset of CRC. Our findings are the
first to demonstrate a link between a genetically defined
subtype of cancer and its corresponding expression of
immune checkpoints in the tumor microenvironment.
The mismatch repair defective subset of CRC selectively
up-regulates at least 5 checkpoint molecules that are
targets of inhibitors currently being clinically tested.
Furthermore, our results were clinically validated in a
Phase II study at Hopkins which showed mismatch-repair
status as a predictor of clinical benefit to immune check-
point blockade with pembrolizumab.
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